On February 10, 2026, the FDA granted a supplemental efficacy approval for Keytruda (pembrolizumab). This regulatory action, designated as BLA 125514 S-186, was submitted by MERCK SHARP DOHME and indicates an update or expansion related to the drug's efficacy profile.
Background
Pembrolizumab, marketed under the brand name Keytruda, is a drug developed by MERCK SHARP DOHME. This supplemental application specifically concerned an update to its efficacy, as classified by the FDA.
What this means
A supplemental efficacy approval from the FDA typically signifies an update to the drug's label regarding its effectiveness. This could involve an expanded indication for an existing patient population, a new indication for a different disease or patient group, or updated efficacy data supporting its current uses. Without further details provided in the source data, clinicians and researchers should consult the updated prescribing information for Keytruda to understand the specific changes and their implications for patient care and treatment strategies.
Source
The information regarding this supplemental approval was obtained from the FDA's official database. The approval for Keytruda (pembrolizumab), identified as BLA 125514 S-186, was granted on February 10, 2026, and is accessible via the accessdata.fda.gov domain.